# US 2026/0167637 A1 · Nlrp3 inflammasome inhibitor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0167637 A1
- Document ID: US20260167637A1
- Status: Published application
- Kind: A1
- Application number: 19/125,837
- Filed: 2023-11-03
- Published: 2026-06-18
- Earliest claimed: 2022-11-04
- Assignees: Transthera Sciences (Nanjing), Inc.
- Applicants: TransThera Sciences (Nanjing), Inc.
- Inventors: Lin Li; Frank Wu
- Web page: https://patentgrep.com/patent/US20260167637A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07B 59/002: {Heterocyclic compounds}
- C07D 237/20: Nitrogen atoms (nitro radicals C07D237/12)
- C07D 253/07: with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 487/04: Ortho-condensed systems
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention belongs to the technical field of medicine, relates to an NLRP3 inflammasome inhibitor and a use thereof, and specifically relates to a compound represented by a general formula (A′) or a pharmaceutically acceptable salt, stereoisomer and deuterated product thereof, the definition of each group being as defined in the description. Studies have shown that the compound represented by general formula (A′) or the pharmaceutically acceptable salt, stereoisomer and deuterated product thereof have high biological activity against an NLRP3 inflammasome, and have important clinical development value for the treatment of NLRP3-related diseases.

## Claims

### Claim 1

A compound represented by general formula (A′) or a pharmaceutically acceptable salt, a stereoisomer or a deuteride thereof:
wherein W is selected from
is selected from a single bond and a double bond;
R1 is independently selected from hydrogen, hydroxy, amino, carboxyl, cyano, nitro, halogen, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, —N(C1-6 alkyl)2, and —S—C1-6 alkyl, or is absent;
R2 is independently selected from hydrogen, hydroxy, amino, carboxyl, cyano, nitro, halogen, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, —N(C1-6 alkyl)2, and —S—C1-6 alkyl, or is absent;
R1 and R2 are each optionally substituted with 1-3 substituents selected from hydroxy, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl;
or
R1 and R2, together with the C or N atom to which they are attached, form a 5-12 membered ring A, wherein the 5-12 membered ring A is optionally substituted with 1-4 substituents selected from hydroxy, amino, carboxyl, cyano, nitro, halogen, carbonyl, oxo, C1-6 alkyl, —NH—C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylsulfonyl, and —N(C1-6 alkyl)2; the 5-12 membered ring is selected from 5-12 membered cycloalkyl, 5-7 membered cycloalkyl, 5-12 membered cycloalkenyl, 5-7 membered cycloalkenyl, 6-12 membered fused cycloalkyl, 5-12 membered heterocyclyl, 5-7 membered heterocyclyl, 6-12 membered fused heterocycle, aryl, 5-12 membered heteroaryl, 8-12 membered fused heteroaryl, and 5-7 membered heteroaryl;
R3 is selected from —(C1-6 alkylene)0-2-NR4R5, —(C1-6 alkylene)0-2-NR4—COR5, —(C1-6 alkylene)0-2-CO—NR4—R5, and —(C1-6 alkylene)0-2-NR4—C1-6 alkylene-R5;
R4 is selected from hydrogen and C1-6 alkyl;
R5 is selected from 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl; R5 is optionally substituted with 1-4 substituents selected from halogen, cyano, amino, hydroxy, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C2-6 alkenylcarbonyl, sulfonyl, C1-6 alkylcarbonyl, ureido C1-6 alkyl, hydroxy C1-6 alkyl, hydrazino, and C1-6 alkylsulfonyl C1-6 alkyl;
the substituent on R5, which is selected from C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, and sulfonyl, is optionally substituted with 1-3 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, 3-6 membered cycloalkyl, and C1-6 alkylsulfonyl;
Y is selected from aryl, 5-14 membered heteroaryl, 3-14 membered heterocyclyl, and 3-12 membered cycloalkyl;
Y is substituted with 1-2 substituents selected from C2-6 alkenyl and C2-6 alkynyl, and can be further optionally substituted with 1-2 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylamino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, sulfonyl, —N(C1-6 alkyl)2, and —S—C1-6 alkyl;
the substituent on Y, which is selected from C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, and sulfonyl, is optionally substituted with 1-3 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, and 3-6 membered cycloalkyl;
the substituent on Y, which is selected from C2-6 alkenyl and C2-6 alkynyl, is optionally substituted with 1-3 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, 3-6 membered cycloalkyl, and halogenated C1-6 alkyl;
when W is selected from
R1 and R2, together with the C atom to which they are attached, do not form a ring.

### Claim 2 (depends on 1)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1,
wherein
W is selected from
R1 is selected from hydrogen, hydroxy, amino, carboxyl, cyano, nitro, halogen, carbonyl, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, 3-7 membered heterocyclyl, 4-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl.

### Claim 3 (depends on 1)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1,
wherein
W is selected from
Y is selected from aryl, 5-14 membered heteroaryl, 3-14 membered heterocyclyl, and 3-12 membered cycloalkyl;
Y is substituted with C2-6 alkynyl, and can be further optionally substituted with 1-2 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylamino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, sulfonyl, —N(C1-6 alkyl)2, and —S—C1-6 alkyl;
the substituent on Y, which is selected from C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, and sulfonyl, is optionally substituted with 1-3 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, and 3-6 membered cycloalkyl;
the substituent on Y, which is selected from C2-6 alkynyl, is optionally substituted with 1-3 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, 3-6 membered cycloalkyl, and halogenated C1-6 alkyl;
R5 is optionally substituted with a substituent selected from hydroxy C1-6 alkyl, C1-6 alkoxy C1-6 alkyl, hydrazino, and ureido C1-6 alkyl.

### Claim 4 (depends on 1)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1,
wherein
W is selected from
Y is selected from aryl, 5-14 membered heteroaryl, 3-14 membered heterocyclyl, and 3-12 membered cycloalkyl;
Y is substituted with C2-6 alkenyl, and can be further optionally substituted with 1-2 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylamino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, sulfonyl, —N(C1-6 alkyl)2, and —S—C1-6 alkyl;
the substituent on Y, which is selected from C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, and sulfonyl, is optionally substituted with 1-3 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, and 3-6 membered cycloalkyl;
the substituent on Y, which is selected from C2-6 alkenyl, is optionally substituted with 1-3 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, 3-6 membered cycloalkyl, and halogenated C1-6 alkyl;
R5 is selected from 3-7 membered heterocyclyl, 5-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl; R5 is optionally substituted with 1-4 substituents selected from halogen, cyano, amino, hydroxy, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C2-6 alkenylcarbonyl, sulfonyl, C1-6 alkylcarbonyl, ureido C1-6 alkyl, hydroxy C1-6 alkyl, hydrazino, and C1-6 alkylsulfonyl C1-6 alkyl.

### Claim 5 (depends on 1)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1,
wherein
W is selected from
at least one of R1 and R2 is selected from C2-6 alkenyl, C2-6 alkynyl, and cyano;
R1 and R2 are each optionally substituted with 1-3 substituents selected from hydroxy, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl;
or
R1 is selected from hydrogen; and R2 selected from is hydrogen.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1,
wherein
W is selected from
Y is selected from aryl, 5-14 membered heteroaryl, 3-14 membered heterocyclyl, and 3-12 membered cycloalkyl;
Y is substituted with propynyl, and can be further optionally substituted with 1-2 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylamino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, sulfonyl, —N(C1-6 alkyl)2, and —S—C1-6 alkyl;
the substituent on Y, which is selected from C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, and sulfonyl, is optionally substituted with 1-3 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, and 3-6 membered cycloalkyl;
the substituent on Y, which is selected from propynyl, is optionally substituted with 1-3 substituents selected from halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, 3-6 membered cycloalkyl, and halogenated C1-6 alkyl;
R5 is selected from 3-7 membered cycloalkyl.

### Claim 8 (depends on 1)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1,
wherein
R5 is selected from 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl; R5 is substituted with 1-2 substituents selected from deuterium, deuterated C1-6 alkyl, ethyl, cyclopropyl, halogen, and halogenated C1-6 alkyl.

### Claim 9 (depends on 1)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1,
wherein
W is selected from
R5 is selected from 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl; R5 is substituted with 1-2 substituents selected from deuterium and hydroxy C1-6 alkyl.

### Claim 10 (depends on 1)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1,
wherein
Y is selected from aryl;
Y is substituted with 1-2 substituents selected from C2-6 alkenyl and C2-6 alkynyl, and can be further substituted with 1-2 substituents selected from hydroxy, halogen, and halogenated C1-6 alkyl.

### Claim 11 (depends on 1)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1,
wherein
W is selected from
when R2 is hydrogen, R1 is not selected from methyl and cyclopropyl.

### Claim 12 (depends on 3)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 3,
wherein R5 is optionally substituted with a substituent selected from hydroxy C1-6 alkyl and C1-6 alkoxy C1-6 alkyl, but the following compounds are excluded:

### Claim 13 (depends on 1)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1,
wherein
W is selected from
R1 is independently selected from hydrogen, halogen, C1-6 alkyl, halogenated C1-6 alkyl, and 3-7 membered cycloalkyl;
R3 is selected from —(C1-6 alkylene)0-2-NR4R5;
R4 is selected from hydrogen and C1-6 alkyl;
R5 is selected from 3-7 membered heterocyclyl and 3-7 membered cycloalkyl; R5 is optionally substituted with 1-4 substituents selected from deuterated C1-6 alkyl, C1-6 alkyl, halogenated C1-6 alkyl, 3-7 membered cycloalkyl, hydroxy, and hydroxy C1-6 alkyl;
Y is selected from aryl;
Y is substituted with C2-6 alkynyl, and can be further optionally substituted with 1-2 substituents selected from hydroxy, C1-6 alkyl, halogenated C1-6 alkyl, and 3-7 membered cycloalkyl;
the C2-6 alkynyl substituent is optionally substituted with a substituent selected from halogen, C1-6 alkyl, 3-6 membered cycloalkyl, and halogenated C1-6 alkyl.

### Claim 14 (depends on 12)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 12, wherein
R1 and R2 are independently selected from hydrogen, halogen, C1-6 alkyl, trifluoromethyl, difluoromethyl, cyclopropyl, and cyclobutyl;
R3 is selected from —NR4R5;
R4 is selected from hydrogen and methyl;
R5 is selected from piperidine, cyclohexyl, cyclopentyl, and cyclobutyl;
Y is selected from a phenyl;
Y is substituted with a substituent selected from ethynyl and propynyl, and can be further optionally substituted with 1-2 substituents selected from hydroxy, C1-6 alkyl, trifluoromethyl, difluoromethyl, and cyclopropyl;
the ethynyl and propynyl substituents are optionally substituted with a substituent selected from halogen, C1-6 alkyl, cyclopropyl, trifluoromethyl, and difluoromethyl;
or
R1 and R2 are independently selected from methyl, trifluoromethyl, difluoromethyl, and cyclopropyl;
R3 is selected from —NR4R5;
R4 is selected from hydrogen;
R5 is selected from piperidinyl;
Y is selected from a phenyl;
Y is substituted with a substituent selected from ethynyl and propynyl, and can be further optionally substituted with 1-2 substituents selected from hydroxy, methyl, trifluoromethyl, difluoromethyl, and cyclopropyl;
the ethynyl and propynyl substituents are optionally substituted with a substituent selected from fluorine, methyl, cyclopropyl, trifluoromethyl, and difluoromethyl;
the substituent on R5 is selected from methyl, ethyl, cyclopropyl, fluorine, chlorine, bromine, difluoroethane, and hydroxyethyl.

### Claim 15 (depends on 13)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 13, wherein
R1 is selected from hydrogen, halogen, C1-6 alkyl, trifluoromethyl, difluoromethyl, cyclopropyl, and cyclobutyl;
R3 is selected from —NR4R5;
R4 is selected from hydrogen and methyl;
R5 is selected from piperidine, cyclohexyl, cyclopentyl, and cyclobutyl;
Y is selected from a phenyl;
Y is substituted with a substituent selected from ethynyl and propynyl, and can be further optionally substituted with 1-2 substituents selected from hydroxy, C1-6 alkyl, trifluoromethyl, difluoromethyl, and cyclopropyl;
the ethynyl and propynyl substituents are optionally substituted with a substituent selected from halogen, C1-6 alkyl, cyclopropyl, trifluoromethyl, and difluoromethyl;
or
R1 is selected from methyl, trifluoromethyl, difluoromethyl, and cyclopropyl;
R3 is selected from —NR4R5;
R4 is selected from hydrogen;
R5 is selected from piperidinyl;
Y is selected from a phenyl;
Y is substituted with a substituent selected from ethynyl and propynyl, and can be further optionally substituted with 1-2 substituents selected from hydroxy, methyl, trifluoromethyl, difluoromethyl, and cyclopropyl;
the ethynyl and propynyl substituents are optionally substituted with a substituent selected from fluorine, methyl, cyclopropyl, trifluoromethyl, and difluoromethyl;
the substituent on R5 is selected from methyl, ethyl, cyclopropyl, fluorine, chlorine, bromine, difluoroethane, and hydroxyethyl.

### Claim 16 (depends on 1)

The compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1, wherein the compound is represented by a formula shown below:

### Claim 17 (depends on 1)

A pharmaceutical composition, comprising the compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 1)

A method for preventing and/or treating NLRP3 inflammasome-associated diseases, comprising administering to a subject in need thereof the compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1.

### Claim 19 (depends on 1)

A method for preventing and/or treating inflammasome-associated diseases, immune diseases, inflammatory diseases, autoimmune diseases, or autoinflammatory diseases, comprising administering to a subject in need thereof the compound or the pharmaceutically acceptable salt, the stereoisomer or the deuteride thereof according to claim 1.

### Claim 20 (depends on 17)

A method for preventing and/or treating NLRP3 inflammasome-associated diseases, comprising administering to a subject in need thereof the pharmaceutical composition of claim 17.

### Claim 21 (depends on 17)

A method for preventing and/or treating inflammasome-associated diseases, immune diseases, inflammatory diseases, autoimmune diseases, or autoinflammatory diseases, comprising administering to a subject in need thereof the pharmaceutical composition according to claim 17.
